Information  X 
Enter a valid email address

Wilmcote Hldgs PLC (WCH)

  Print      Mail a friend

Thursday 07 June, 2018

Wilmcote Hldgs PLC

Statement re media speculation

RNS Number : 6111Q
Wilmcote Holdings PLC
07 June 2018
 

7th June 2018                    This announcement contains inside information 

 

 

Wilmcote Holdings plc

 

Statement re media speculation

 

Wilmcote Holdings plc ('Wilmcote'), established in 2017 to acquire and subsequently develop target businesses in the chemicals sector, notes the recent press speculation and confirms that it is in discussions with Platform Specialty Products ('Platform') regarding a potential acquisition of its Agricultural Solutions segment, Arysta LifeScience.

 

The discussions are ongoing and as such there is no certainty that any transaction will proceed between Wilmcote and Platform. A further announcement will be made as appropriate.

 

In accordance with Rule 14 of the AIM Rules, Wilmcote's ordinary shares will be suspended from trading on AIM with effect from 7.30am, 7th June. The Company's ordinary shares will remain suspended pending compliance with Rule 14 or until such time an announcement is released confirming that the potential acquisition is not proceeding. 

 

-ENDS-

 

Teneo (Financial PR)                                                                                      Tel: +44 (0) 7703 330 269
Charles Armitstead/ Rosie Oddy               

 

 

Numis Securities Limited (Nominated Adviser and Broker)                  Tel: +44 (0) 20 7260 1000

Jamie Lillywhite

Jamie Loughborough

 

 

Adrian Whitfield is Chief Executive Officer of Wilmcote Holdings plc, which has its offices at 11 Buckingham Street, London WC2N 6DF and has the LEI number 2138004EUUU11OVHZW75.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
SPCEALKXEAFPEEF

a d v e r t i s e m e n t